百济神州 BeiGene  
百济神州是一家总部设在北京的中国生命科学生物科技公司，致力于探索和开发对中国和亚太地区常见癌症有效的新型抗肿瘤药物。

我们的研发策略将包括开发我们自己在中国实验室发现的新药和从合作伙伴引进的对中国和亚太地区常见癌症有潜在疗效的新药。

为完善我们的研发能力，百济神州正在中国创造一个从实验室到临床试验的强大整合研发平台，用于识别癌症患者中最有可能受益于相关药物或治疗方法的病人亚群。通过理解对药物的敏感性和靶标分子之间的关系, 我们将会研发出更有效和更安全的新药。

我们正在以下领域建立杰出的团队：

全新的小分子药物和生物药物的研发
侧重于在患者中对生物标志物识别和确认的转化研究
基于人类肿瘤基因分型和基因表达谱的生物信息学
2个中国临床试验项目
以下几个方面实力的结合带给我们独特的优势：

中国和西方的研发知识和临床实践
大制药公司的严谨性和稳健性与小生物技术公司的创业精神
中国和西方的创业文化
百济神州总部设立于中国北京。

BeiGene is a Chinese life sciences biotechnology company based in Beijing that is focused on discovering and developing innovative oncology drugs that will address unmet medical needs in cancers that are prevalent in China and the Asia-Pacific region.

Our compound portfolio will encompass novel drugs that evolve out of our discovery laboratories in China that have potential for high impact in the treatment of Chinese and Asian cancers.

To complement our discovery and development capabilities, BeiGene is creating a robust platform in China to enable the identification of specific subsets of patient populations that will identify patients who are most likely to benefit from the use of specific drugs or treatments. Understanding the link between treatment sensitivity and molecular targets will direct us to develop future drug candidates with greater efficacy and safety.

We are building core excellence in:

novel drug discovery in the areas of both small molecules and biologicals
translational research with an emphasis on biomarker identification and validation in patients
bioinformatics based on human tumor genotyping and expression profiling
2 China clinical development
Our unique organization synergistically combines the strengths of:

Chinese and Western scientific knowledge and medical practice
rigor and robustness from large pharma with biotech entrepreneurialism
Chinese and Western start-up culture
BeiGene is headquartered and operates from Beijing, China.